UBS Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135.11

Benzinga Newsdesk www.benzinga.com Neutral 47.6%

Neg 0% Neu 47.6% Pos 0%

UBS analyst Michael Yee downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral and raises the price target from $100 to $135.11.